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Abstract 
Context: A previous genome‑wide association study showed that a genetic variant of sortilin was associated with 
the risk of coronary artery disease (CAD). However, the role of circulating sortilin is still unknown. We investigated the 
potential role of plasma sortilin as a biomarker for CAD and diabetes mellitus.
Methods: We enrolled statin‑naïve subjects with CAD (n = 31) who underwent coronary artery bypass surgery and 
control subjects (n = 116) who were free from CAD as evaluated by coronary CT angiography. The presence of diabe‑
tes mellitus was evaluated and plasma sortilin levels were measured with a commercial ELISA kit.
Results: Plasma sortilin levels were higher in subjects with CAD and subjects with diabetes mellitus than in those 
without CAD or diabetes mellitus. Subjects in the highest sortilin tertile group were older and had higher glucose and 
HbA1c levels, but lipid profiles in the three tertile groups were comparable. Multivariable logistic regression analysis 
revealed that sortilin levels were independently associated with CAD. In addition, the receiver operating characteristic 
curve analysis showed that plasma sortilin levels could identify the presence of CAD or diabetes mellitus.
Conclusions: Elevated circulating sortilin levels are associated with CAD and diabetes mellitus and can be used as a 
biomarker of both diseases in statin‑naïve subjects.
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Background
The number of adults with diabetes mellitus has nearly 
quadrupled in the USA over the past 30  years [1]. In 
addition, it is estimated that the global prevalence of dia-
betes mellitus will increase by 54% from 2010 to 2030 
[2]. In Korea, the prevalence of diabetes mellitus is also 
increasing and the last national survey showed that the 
prevalence among adults 30  years or older is 13.7% [3]. 
However, the majority of individuals with diabetes are 
not aware of their condition and the rate may be up to 
30% [3]. Therefore, biomarkers for diabetes mellitus 
should be developed to improve the identification of 
high-risk subjects.
In patients with diabetes mellitus, the leading cause of 
death is cardiovascular disease, even though the rates of 
cardiovascular disease declined between 1990 and 2010 
[4]. It is unquestionable that diabetes mellitus is the most 
important risk factor for cardiovascular disease [5]. In 
this context, a biomarker for diabetes mellitus could be 
used for the prediction of CAD and vice versa. In fact, 
there are common shared biomarkers for CAD and dia-
betes mellitus [6, 7]. These biomarkers are useful for dis-
tinguishing patients at high risk for CAD [3, 8] and may 
be good candidates as therapeutic targets. In this context, 
investigation of biomarkers for both CAD and diabetes 
mellitus has important clinical implications.
The Wellcome Trust Case Control Consortium study 
showed that a single nucleotide polymorphism at the 
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1p13 locus was associated with the risk of CAD [9]. Sub-
sequent studies demonstrated that the SORT1 gene was 
associated with hepatic lipid metabolism [10] and low-
density lipoprotein (LDL)-cholesterol levels [11]. The 
SORT1 gene encodes sortilin, which belongs to the mam-
malian vacuolar protein sorting 10 protein domain family 
[12]. Sortilin is located mainly within cells in sites such as 
the trans-Golgi network, and it is also located in the cell 
membrane [12] and systemic circulation [13]. Few stud-
ies have reported that soluble sortilin and the propeptide 
fragment of its ligand, proneurotensin, were associated 
with cardiovascular risk factors [14, 15]. Ogawa demon-
strated that soluble sortilin levels were positively asso-
ciated with cardiovascular risk factors, but that soluble 
sortilin levels were lower in patients with CAD than con-
trols [14]. In another study from the Framingham Heart 
Study, increased circulating proneurotensin was asso-
ciated with a higher rate of cardiovascular events [15]. 
Therefore, there is some discrepancy between the two 
studies of prediction of CVD using these two circulating 
molecules related to sortilin. In this study, we measured 
circulating sortilin levels, and tested whether the meas-
urement of circulating sortilin can be used as a biomarker 
of both CVD and diabetes mellitus.
Methods
Study population
We enrolled subjects with and without confirmed CAD. 
The subjects with CAD were recruited from the Tho-
racic Surgery Department of the Seoul National Uni-
versity Bundang Hospital (SNUBH). They underwent 
coronary artery bypass graft (CABG) surgery because of 
acute myocardial infarction, unstable angina, or stable 
angina with three-vessel disease. The subjects that were 
free from CAD, as evaluated by coronary CT angiogra-
phy, were recruited from the outpatient clinic of Endo-
crinology Department at the same hospital. We excluded 
subjects who had been treated with statins within the 
previous 3  months or whose medical records were not 
available. A total of 31 subjects with CAD and 116 sub-
jects without CAD were enrolled from May 2012 to 
January 2015. Of these, 43 (29.3%) subjects were diag-
nosed with diabetes mellitus. The study was approved by 
the Institutional Review Board of the SNUBH (IRB No 
B1203/147-006) and all subjects gave informed consent.
Medical history and diagnosis
We defined CAD as acute myocardial infarction or 
angina pectoris that needed to be treated with CABG 
surgery. The definition of normal coronary arteries was 
the absence of luminal stenosis of ≥50% with a coronary 
artery calcium score <10. Diabetes mellitus was defined 
as a fasting plasma glucose ≥126  mg/dl and/or HbA1c 
≥6.5% or treatment with antidiabetes medication. Medi-
cal records were reviewed and medical history and clini-
cal characteristics such as age, sex, body weight, height, 
systolic and diastolic blood pressure were obtained. Bio-
chemical analysis was performed immediately before 
surgery or within 3 months of coronary CT angiography. 
Nonfasting blood samples were obtained and centrifuged 
at 3000 rpm for 10 min at 4 °C. The plasma was stored at 
−80 °C until analysis.
Biochemical assays
The plasma levels of glucose and HbA1c were measured 
by the hexokinase method and high-performance liq-
uid chromatography, respectively. Total cholesterol, tri-
glyceride, high-density lipoprotein (HDL)-cholesterol, 
and LDL-cholesterol levels were measured by relevant 
enzymatic assays and the glycerol-3-phosphate oxidase 
peroxide method. The high-sensitive C-reactive protein 
(hs-CRP) was measured by latex-enhanced turbidometric 
immunoassay (Denka Seiken Co., Tokyo, Japan). These 
laboratory analyses were performed by the central labo-
ratory of SNUBH. Circulating plasma sortilin was meas-
ured using a commercial enzyme-linked immunosorbent 
assay (ELISA) (Cusabio ELISA kits, Cosmo Bio, Carlsbad, 
CA, USA). This ELISA kit can detect sortilin levels of 
46.88–3000 pg/ml with a coefficient of variation <8% for 
intra-assay precision and <10% for interassay variation.
Statistical analysis
Continuous variables are presented as mean and stand-
ard deviation and categorical variables are presented as 
percentages. The differences between two groups were 
analyzed by 2-tailed Student t test or nonparametric t 
test and age-adjusted analysis of covariance. Categorical 
variables were compared using the Chi square test. Com-
parison between the three tertile groups was performed 
using one-way analysis of variance (ANOVA) followed 
by least significant difference (LSD) post hoc analysis. A 
log transformation was applied to glucose, HbA1c, tri-
glyceride, hs-CRP, and sortilin levels prior to performing 
ANOVA and logistic regression analysis. The association 
with CAD or diabetes mellitus was evaluated by univari-
able and multivariable logistic regression analysis. The 
area under the receiver-operating characteristics (ROC) 
curve was calculated to test its predictive discrimination 
of CAD. The optimal cut-off value was determined using 
the maximum sum of sensitivity and specificity based 
on the Youden-Index. Statistical analysis was performed 
using IBM SPSS Statistics for Windows, version 20.0 
(IBM Corp., Armonk, NY, USA). For all tests, P  <  0.05 
was considered to be significant.
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Results
The clinical and biochemical characteristics of subjects 
with or without CAD are shown in Table 1. Subjects with 
CAD were older and had higher systolic blood pressure 
and blood glucose levels than their counterparts. They 
showed lower HDL- and LDL-cholesterol levels than 
subjects without CAD and included a higher proportion 
of subjects diagnosed with diabetes mellitus, hyperten-
sion, and dyslipidemia. Circulating plasma sortilin levels 
were higher in subjects with CAD than those without 
CAD (Fig. 1). The significance remained after age adjust-
ment. Two subjects that had extreme values for sortilin 
(6.47 and 6.75 ng/ml) did not have CAD. However, when 
we eliminated these two outliers the study results were 
not changed. Overall, 26 of 31 subjects with CAD took 
aspirin. We did not see any significant difference in circu-
lating sortilin levels between aspirin users and non-users 
(1.72 ± 0.45 vs. 1.86 ± 0.42 ng/ml, P = 0.548).
Next, we compared the variables in subjects with or 
without diabetes mellitus (Table  2). The subjects with 
diabetes mellitus showed similar clinical deterioration to 
the subjects with CAD. The sortilin levels were signifi-
cantly higher in subjects with diabetes mellitus compared 
with those without diabetes mellitus (1.57  ±  0.54, and 
1.34 ± 1.0 ng/ml, P = 0.006).
Table 3 shows the general characteristics of study par-
ticipants grouped according to sortilin tertiles. The mean 
age of subjects in tertile 1 was lower than those in tertiles 
2 and 3. Body weight, blood pressure, and lipid profiles 
were comparable between the three tertile groups. How-
ever, blood glucose and HbA1c levels were higher in 
subjects in tertiles 2 and 3 than in subjects in tertile 1. 
In addition, more subjects in tertile 3 were diagnosed as 
having diabetes mellitus and CAD.
As shown in Table  4, univariable logistic regression 
analysis revealed that age, systolic blood pressure, log 
glucose, log HbA1c, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, log hs-CRP, and log sortilin were associ-
ated with CAD. We included these variables in multivari-
able logistic regression analysis but omitted log glucose, 
Table 1 Clinical and biochemical characteristics of study participants classified according to coronary artery disease
Data are expressed as mean ± SD, or %. CAD coronary artery disease, DM diabetes mellitus, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood 
pressure, TC total cholesterol, LDL-C LDL cholesterol, HDL-C HDL cholesterol, TG triglyceride, HTN hypertension
P values for student’s t test or nonparametric t test or Chi square test
* P values for age-adjusted ANCOVA
Total subjects CAD (−), n = 116 CAD (+), n = 31 P value P value*
Age (years) 55.5 ± 11.0 52.9 ± 9.2 65.4 ± 11.8 <0.001 N/a
Men (%) 69.4 66 84 0.052 N/a
Body weight (kg) 65.3 ± 11.0 65.8 ± 11.5 63.3 ± 8.60 0.203 0.886
BMI (kg/m2) 23.9 ± 2.8 24.1 ± 2.9 23.4 ± 2.5 0.213 0.587
SBP (mmHg) 122.2 ± 17.0 120.5 ± 16.4 128.6 ± 18.0 0.019 0.015
DBP (mmHg) 73.7 ± 11.7 74.1 ± 12.2 72.3 ± 9.5 0.438 0.633
Glucose (mg/dl) 107.0 ± 1.4 102.0 ± 30.9 161.0 ± 77.0 <0.001 <0.001
HbA1c (%) 6.2 ± 1.2 6.2 ± 1.4 6.9 ± 1.5 0.004 0.068
TC (mg/dl) 194.0 ± 40.3 202.1 ± 35.3 164.0 ± 43.9 <0.001 <0.001
LDL‑C (mg/dl) 110.1 ± 26.8 112.6 ± 26.0 100.6 ± 28.4 0.026 0.097
HDL‑C (mg/dl) 49.1 ± 12.3 52.0 ± 11.7 38.1 ± 7.2 <0.001 <0.001
TG (mg/dl) 132.7 ± 66.9 131.9 ± 67.4 135.6 ± 65.9 0.623 0.345
hs‑CRP (mg/dl) 0.28 ± 0.71 0.11 ± 0.22 0.87 ± 1.26 <0.001 <0.001
DM (%) 29.3 19.8 64.5 <0.001 N/a
HTN (%) 53.7 43.1 93.5 <0.001 N/a
Dyslipidemia (%) 37.4 28.4 71.0 <0.001 N/a
Fig. 1 Circulating sortilin levels depending on the existence of coro‑
nary artery disease. Data are shown as mean ± SD. ***P < 0.001 using 
a nonparametric t test
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and total cholesterol to avoid collinearity. Multivariable 
logistic regression analysis indicated that age, HDL-cho-
lesterol, log hs-CRP, and log sortilin were independently 
associated with the presence of CAD.
The ability of the area under the receiver operat-
ing characteristic (ROC) curve based on sortilin levels 
to predict the presence of CAD was 0.725 (Fig.  2). The 
optimal cut-off values of sortilin were 1.35 ng/ml (80.6% 
sensitivity and 53.0% specificity) to detect CAD. We per-
formed same analysis in the subgroup without CAD. In 
this analysis we found that the area under ROC curve for 
sortilin levels to predict the presence of diabetes mellitus 
was 0.681, and the asymptotic significance was 0.007.
Discussion
This is the first study to demonstrate that circulating sor-
tilin levels measured by commercial ELISA are associated 
with both CAD and diabetes mellitus. Subjects with CAD 
or diabetes mellitus had higher sortilin levels than control 
subjects, and plasma sortilin levels were independently 
associated with CAD. In subgroup of subjects free from 
CAD, circulating sortilin levels were also associated with 
the presence of diabetes mellitus. These results demon-
strated that sortilin levels can be used as a biomarker for 
CAD and diabetes mellitus, further studies are required 
Table 2 Clinical and  biochemical characteristics and  sor-
tilin levels in  subgroup without  coronary artery disease 
according to their diabetes mellitus status
Data are expressed as mean ± SD, or %. CAD coronary artery disease, DM 
diabetes mellitus, BMI body mass index, SBP systolic blood pressure, DBP 
diastolic blood pressure, TC total cholesterol, LDL-C LDL cholesterol, HDL-C HDL 
cholesterol, TG triglyceride, HTN hypertension
P values for student’s t test or nonparametric t test or Chi square test
DM (−), n = 93 DM (+), n = 23 P value
Age (years) 52.5 ± 8.3 54.5 ± 12.0 0.444
Men (%) 31.2 47.8 0.148
Body weight (kg) 65.7 ± 11.4 66.0 ± 12.4 0.916
BMI (kg/m2) 23.8 ± 2.8 25.1 ± 2.9 0.058
SBP (mmHg) 120.2 ± 16.0 121.7 ± 18.2 0.696
DBP (mmHg) 73.8 ± 12.3 75.3 ± 11.8 0.614
Glucose (mg/dl) 90.8 ± 12.9 147.3 ± 40.3 <0.001
HbA1c (%) 5.7 ± 0.3 8.5 ± 1.8 <0.001
TC (mg/dl) 202.6 ± 34.5 200.1 ± 39.2 0.764
LDL‑C (mg/dl) 111.2 ± 24.3 118.3 ± 31.8 0.243
HDL‑C (mg/dl) 52.6 ± 12.0 49.6 ± 10.3 0.272
TG (mg/dl) 129.0 ± 67.9 143.3 ± 65.5 0.255
hs‑CRP (mg/dl) 0.17 ± 0.52 0.56 ± 0.98 <0.001
Sortilin (ng/ml) 1.34 ± 1.0 1.57 ± 0.54 0.006
HTN (%) 61.1 41.2 0.008
Dyslipidemia (%) 71.0 73.9 0.999
Table 3 General characteristics of patients by tertiles of circulating sortilin level
Data are expressed as mean ± SD, or %. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, LDL-C LDL cholesterol, 
HDL-C HDL cholesterol, TG triglyceride, DM diabetes mellitus, CAD coronary artery disease, HTN hypertension
Log-transformation was used for variables (glucose, HbA1c, triglyceride, hs-CRP, and sortilin) before statistical analysis. P values for one-way analysis of variance 
(ANOVA)
a,b  The data with different superscript letters are significantly different
Tertiles of circulating sortilin levels P value
Tertile 1 (<1.17 ng/ml) n = 49 Tertile 2 (1.17–1.59 ng/ml) n = 49 Tertile 3 (≥1.60 ng/ml) n = 49
Age (years) 50.4 ± 6.5a 60.0 ± 9.9b 56.2 ± 13.4b <0.001
Men (%) 73.5 67.3 67.3 0.750
Body weight (kg) 67.4 ± 10.2 64.2 ± 11.1 64.2 ± 11.5 0.249
BMI (kg/m2) 24.1 ± 2.3 23.9 ± 3.1 23.8 ± 3.0 0.890
SBP (mmHg) 119.9 ± 16.3 122.8 ± 15.9 124.0 ± 18.8 0.473
DBP (mmHg) 73.8 ± 11.7 73.9 ± 10.5 73.5 ± 12.9 0.985
Glucose (mg/dl) 94.0 ± 1.3a 113.3 ± 1.4b 115.1 ± 1.5b 0.003
HbA1c (%) 5.9 ± 1.1a 6.3 ± 1.2a 6.6 ± 1.3b 0.011
TC (mg/dl) 202.2 ± 34.9 191.7 ± 41.5 188.2 ± 43.5 0.206
LDL‑C (mg/dl) 111.1 ± 22.5 109.9 ± 25.3 109.3 ± 32.3 0.946
HDL‑C (mg/dl) 51.5 ± 13.7 49.7 ± 10.9 46.1 ± 11.9 0.082
TG (mg/dl) 122.0 ± 1.6 110.8 ± 1.7 118.9 ± 1.7 0.631
hs‑CRP (mg/dl) 0.10 ± 0.15 0.28 ± 0.56 0.49 ± 1.09 0.015
DM (%) 8.2 34.7 44.9 <0.001
CAD (%) 0 26.5 36.7 <0.001
HTN (%) 14.3 75.5 71.4 <0.001
Dyslipidemia (%) 30.6 32.7 49.0 0.120
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to validate these results and to determine the relationship 
between sortilin and glucose metabolism.
Sortilin is one of three neurotensin receptors, neu-
rotensin receptor-3 [16]. The level of proneurotensin, the 
propeptide of neurotensin, was reported to be related 
to the risk of incident diabetes mellitus in a prospective 
cohort study [17]. In this cohort, individuals with higher 
circulating proneurotensin had a higher incidence of 
diabetes mellitus, with a hazard ratio of 1.28 (95% con-
fidence interval 1.07–1.50, P  =  0.003). In addition, in 
another human study, plasma proneurotensin levels were 
higher in insulin-resistant obese subjects [18]. In our 
study, plasma levels of sortilin, a receptor for neuroten-
sin, were related to diabetes mellitus and insulin resist-
ance. Therefore, sortilin/neurotensin signaling might 
play an important role in insulin signaling. One possible 
explanation for this is suggested by the role of sortilin in 
glucose transporter-4 translocation in adipocytes [19]. 
Furthermore, neurotensin deficient mice were resist-
ant to high-fat diet-induced obesity, and neurotensin 
decreases AMP-activated protein kinase activity via sor-
tilin [18]. Our study results add new evidence for the 
link between sortilin and insulin signaling and glucose 
regulation.
Our results are noteworthy because we included sub-
jects using strict criteria that minimized possible bias. 
First, we excluded subjects taking statin therapy. A pre-
vious study showed that treatment with pitavastatin or 
pravastatin for 8 months significantly decreased the cir-
culating sortilin levels compared with baseline by 8% for 
pitavastatin and 16% for pravastatin [20]. Therefore, sta-
tin therapy has an impact on circulating sortilin levels, 
and we eliminated this bias by including only statin-naïve 
subjects. Second, we defined a normal coronary artery 
based on coronary CT angiography, a test that has a high 
negative predictive value [21]. Therefore, our data were 
not confounded by uncertainty about the presence of 
Table 4 Univariable and multivariable logistic regression analyses for coronary artery disease
CAD coronary artery disease, DM diabetes mellitus, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG triglyceride, 
HDL-C HDL cholesterol, LDL-C LDL cholesterol




OR (95% CI) P value OR (95% CI) P value
Age (years) 1.14 (1.08–1.20) <0.001 1.08 (1.00–1.17) 0.04
BMI (kg/m2) 0.91 (0.79–1.06) 0.213 – –
SBP (mmHg) 1.03 (1.00–1.05) 0.021 1.03 (0.98–1.08) 0.262
DBP (mmHg) 0.99 (0.85–1.02) 0.435 – –
Log glucose (mg/dl) 41.69 (9.19–189.12) <0.001 – –
Log HbA1c (%) 10.06 (1.54–65.87) 0.016 0.12 (0.02–7.61) 0.124
TC (mg/dl) 0.97 (0.96–0.99) <0.001 – –
Log TG (mg/dl) 1.13 (0.52–2.48) 0.757 – –
HDL‑C (mg/dl) 0.86 (0.81–0.91) <0.001 0.82 (0.72–0.93) 0.002
LDL‑C (mg/dl) 0.98 (0.97–1.00) 0.028 1.01 (0.98–1.05) 0.513
Log hs‑CRP (mg/dl) 2.64 (1.80–3.88) <0.001 2.27 (1.28–4.04) 0.005
Log sortilin (ng/ml) 4.17 (1.68–10.35) 0.002 5.29 (1.06–26.51) 0.043
Fig. 2 ROC curve analysis of the ability of sortilin to predict the pres‑
ence of coronary artery disease
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CAD, in contrast to other studies that define the absence 
of CAD from the subjects’ medical history. Third, we 
analyzed the data by several statistical methods, and the 
results were consistent.
Genome-wide association studies have provided good 
insight into the relationship between lipid metabolism 
and CAD [22, 23]. From these studies the cardiovascular 
phenotype of genetic variants seems to depend on eth-
nicity or the presence of diabetes mellitus. Variants in 
the SORT1 locus also showed an association with lipid 
metabolism and CAD [24]. However, the effect of this 
genetic variant on blood sortilin levels has not been clari-
fied. In contrast to our data, a Japanese study [14] showed 
that the soluble sortilin levels were lower in subjects with 
CAD than in controls. The Japanese study used a differ-
ent type of assay to measure the sortilin levels, and the 
majority of study subjects were being treated with statins. 
Therefore, when we used sortilin as a biomarker, we 
made an effort to standardize the measurement of blood 
sortilin levels and elucidate the impact of various medi-
cations on its levels.
Sortilin is expressed widely, including in the nervous 
system, liver, adipose tissue, and in immune cells includ-
ing macrophages [25]. Whole-body sortilin-knockout 
mice had decreased plasma HDL- and LDL-cholesterol 
levels accompanied by attenuation of atherosclerotic 
lesions [10] and vascular calcification [26]. Similarly, 
macrophage sortilin-deficient mice showed reduced ath-
erosclerotic lesions because of reduced LDL uptake by 
macrophages [27]. In contrast, serum LDL-cholesterol 
levels were decreased rather than increased after overex-
pression of sortilin in the liver using adenovirus [28]. This 
study used sortilin molecules including the C-terminus, 
and this form of sortilin is likely to include the trans-
membrane region. This type of sortilin enhanced LDL 
clearance via an LDL receptor-independent pathway. 
A subsequent study demonstrated that hepatic sortilin 
reduces hepatic apolipoprotein B secretion and increases 
LDL catabolism [29]. In contrast, another study using 
sortilin without the C-terminal region enhanced hepatic 
very low density lipoprotein (VLDL), leading to increased 
LDL levels in the blood [10]. Therefore, the role of sor-
tilin in lipid metabolism seems to be differ according to 
its structure, location, and target tissue. To our knowl-
edge, there are no previous studies of the correlation 
between tissue and circulating levels of sortilin. In our 
study, we confirmed that higher circulating sortilin levels 
were related to an increased risk of CAD. However, we 
did not see any significant correlation between circulat-
ing sortilin levels and LDL-cholesterol or hepatic sortilin 
content. In the case of LDL-cholesterol, one type of sor-
tilin can reduce VLDL secretion, while the other type of 
sortilin can enhance internalization of LDL-cholesterol. 
In addition, the exact role of circulating sortilin, the 
type measured in our study, is not known. There may be 
mechanisms other than lipid metabolism that contribute 
to the association between circulating sortilin and CAD. 
Interestingly, in the subgroup of subjects without CAD 
the insulin resistance calculated by HOMA-IR was posi-
tively correlated with circulating sortilin levels (Spear-
man’s ρ = 0.513, P = 0.015). Insulin resistance could be 
a link between sortilin, atherosclerosis and diabetes mel-
litus. Further mechanistic studies are needed to confirm 
this hypothesis.
Limitations
Our study has several limitations. First, this is a cross-
sectional study, so we could not predict future devel-
opment of CAD and diabetes mellitus. The suggested 
cut-off value of sortilin for discriminating CAD had rela-
tively low specificity, so we were unable to diagnose CAD 
solely based on blood sortilin level. A large-scale pro-
spective cohort study is needed to confirm the usefulness 
of circulating sortilin for screening of CAD. In addition, 
usefulness of sortilin to screen or predict diabetes melli-
tus is doubtful, because measuring plasma glucose level is 
more practical than assaying for sortilin. Second, we did 
not analyze the sortilin levels according to disease sever-
ity, e.g., comparing subclinical and clinical atherosclero-
sis, or prediabetes to overt diabetes. Therefore, we cannot 
generalize our data to a broad range of CAD includ-
ing subclinical atherosclerosis. Third, even though we 
adjusted for the age difference between groups, the age 
discrepancy could be a confounder. Furthermore, statisti-
cal analysis for DM was not feasible because of the small 
number of subjects without diabetes mellitus who under-
went CABG. Fourth, we did not investigate the influence 
of antidiabetic and antihypertensive medication. Finally, 
we had no data concerning the presence of single nucleo-
tide polymorphisms of sortilin.
Conclusions
Circulating sortilin level was associated with both CAD 
and diabetes mellitus. Elevated circulating sortilin levels 
were an independent risk factor for CAD and could be 
a useful biomarker for these two diseases, especially in 
statin-naïve subjects.
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